- Home
- DCOMP vs SCLXW Comparison
DCOMP vs SCLXW Comparison
Compare DCOMP & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCOMP
- SCLXW
- Stock Information
- Founded
- DCOMP N/A
- SCLXW N/A
- Country
- DCOMP United States
- SCLXW United States
- Employees
- DCOMP 887
- SCLXW 31
- Industry
- DCOMP Major Banks
- SCLXW Biotechnology: Pharmaceutical Preparations
- Sector
- DCOMP Finance
- SCLXW Health Care
- Exchange
- DCOMP Nasdaq
- SCLXW Nasdaq
- Market Cap
- DCOMP N/A
- SCLXW N/A
- IPO Year
- DCOMP N/A
- SCLXW N/A
- Fundamental
- Price
- DCOMP $18.90
- SCLXW $0.22
- Analyst Decision
- DCOMP
- SCLXW
- Analyst Count
- DCOMP 0
- SCLXW 0
- Target Price
- DCOMP N/A
- SCLXW N/A
- AVG Volume (30 Days)
- DCOMP N/A
- SCLXW 4.0K
- Earning Date
- DCOMP N/A
- SCLXW 03-07-2025
- Dividend Yield
- DCOMP N/A
- SCLXW N/A
- EPS Growth
- DCOMP N/A
- SCLXW N/A
- EPS
- DCOMP N/A
- SCLXW N/A
- Revenue
- DCOMP N/A
- SCLXW $55,152,000.00
- Revenue This Year
- DCOMP N/A
- SCLXW N/A
- Revenue Next Year
- DCOMP N/A
- SCLXW N/A
- P/E Ratio
- DCOMP N/A
- SCLXW N/A
- Revenue Growth
- DCOMP N/A
- SCLXW 22.02
- 52 Week Low
- DCOMP N/A
- SCLXW $0.18
- 52 Week High
- DCOMP N/A
- SCLXW $0.18
- Technical
- Relative Strength Index (RSI)
- DCOMP 48.62
- SCLXW 49.61
- Support Level
- DCOMP $18.70
- SCLXW $0.16
- Resistance Level
- DCOMP $18.97
- SCLXW $0.23
- Average True Range (ATR)
- DCOMP 0.23
- SCLXW 0.05
- MACD
- DCOMP 0.03
- SCLXW -0.00
- Stochastic Oscillator
- DCOMP 68.75
- SCLXW 45.34
About DCOMP Dime Community Bancshares Inc. Fixed-Rate Non-Cumulative Perpetual Preferred Stock Series A
Dime Community Bancshares Inc operates as a holding company. It gathers deposits from customers within its market area and via the internet and invests them in multifamily residential, commercial real estate, commercial and industrial (C&I) loans, and one-to-four family residential real estate loans, as well as mortgage-backed securities, obligations of the U.S. government and government- sponsored enterprises (GSEs), and corporate debt and equity securities. The company has one reportable segment which is Community Banking.
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.